Personalised Decision Support for Heart Valve Disease
Valvular Heart Disease currently affects 2.5% of the population, but is overwhelmingly a disease of the elderly and consequently on the rise. It is dominated by two conditions, Aortic Stenosis and Mitral Regurgitation, both of whi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
iCARE4CVD
INDIVIDUALISED CARE FROM EARLY RISK OF CARDIOVASCULAR DISEAS...
20M€
Cerrado
TEC2013-42140-R
PROCESADO DE SEÑALES GUIADO POR LA FISIOLOGIA PARA LA ESTRAT...
94K€
Cerrado
VPH2
Virtual Pathological Heart of the Virtual Physiological Huma...
6M€
Cerrado
ARTreat
Multi level patient specific artery and atherogenesis model...
9M€
Cerrado
BES-2017-080587
MULTI-SCALE PHYSIOLOGY-DRIVEN COMPUTATIONAL TOOLS TO ASSIST...
93K€
Cerrado
COMHEART2CLINIC
Translation of Computational Heart Models into the Clinic
30K€
Cerrado
Información proyecto EurValve
Duración del proyecto: 38 meses
Fecha Inicio: 2015-11-10
Fecha Fin: 2019-01-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Valvular Heart Disease currently affects 2.5% of the population, but is overwhelmingly a disease of the elderly and consequently on the rise. It is dominated by two conditions, Aortic Stenosis and Mitral Regurgitation, both of which are associated with significant morbidity and mortality, yet which pose a truly demanding challenge for treatment optimisation. By combining multiple complex modelling components developed in recent EC-funded research projects, a comprehensive, clinically-compliant decision-support system will be developed to meet this challenge, by quantifying individualised disease severity and patient impairment, predicting disease progression, ranking the effectiveness of alternative candidate procedures, and optimising the patient-specific intervention plan. This algorithmically-driven process will dramatically improve outcomes and consistency across Europe in this fast-growing patient group, maximising individual, societal and economic outcomes.